What the New US “Fragility Index” Means for API Buyers
On October 6, 2026, the API Innovation Center (APIIC), a St. Louis-based nonprofit, launched the National Fragility Index (NFI), described as the first benchmark built to measure and track structural fragility across U.S. pharmaceutical supply chains. For anyone who buys active pharmaceutical ingredients, the headline isn’t the index itself. It’s the shift it signals: API supply chain fragility is no longer a vague worry raised after a shortage. It is becoming something regulators, policymakers and customers can score, drug by drug.
This guide explains what the index measures, what its early findings say, and, most usefully, what API buyers can do now to show that their own supply chain holds up.
What Is the National Fragility Index?
According to APIIC’s launch announcement, the NFI assesses vulnerabilities down to individual drug product codes and sets a baseline for judging whether investments in supply chain security reduce risk over time. It weighs five factors:
- Geopolitical conditions
- Regulatory compliance
- Financial stability
- Manufacturing location
- Clinical impact
The initial analysis covers more than 400 medicines across 131 treatment categories. Of those, 14 rate Severe and 71 rate High for fragility, roughly one in five of the medicines scored.
What the Early Findings Tell Us
A few numbers from the launch are worth knowing:
- More than 550 million prescriptions filled in 2023 were for medicines rated High or Severe.
- Nearly six in ten of the medicines analyzed had at least one recorded shortage, and for those, the median shortage lasted over two years.
- At least 11 APIs on the ASPR list of 86 essential medicines have a U.S. manufacturer, yet none of them supply U.S. drugmakers.
Two examples that matter for buyers
Pantoprazole rates Severe. Its API comes from 36 suppliers in 12 countries, and APIIC found no U.S. source. The takeaway: having many suppliers did not make the supply chain robust. Supplier count alone is not resilience.
Metoprolol rates High. It has no domestic API source and has had two shortages since 2015, averaging nearly five years each.
Both examples show that fragility is a structural property of a supply chain, not just a question of how many names are on an approved vendor list.
What the Index Is Not
Be careful about reading too much into it. The NFI scores medicines, not individual suppliers. It is a U.S.-focused benchmark, and the launch announcement does not name specific source countries. It does not rate any manufacturer, Indian or otherwise. So no supplier can claim to have “passed” the index.
What it does give buyers is a useful frame. If regulators and customers are going to ask whether your supply is fragile, you need evidence-based answers ready.
Mapping the Five Index Factors to Your Supplier Checks
The factors the NFI weighs line up closely with checks a buyer can run on any API supplier today.
| Index factor | What to ask your API supplier |
|---|---|
| Geopolitical conditions | Where are the key starting materials and intermediates sourced from? Is there a single-country dependency? |
| Regulatory compliance | Can you show a current GMP certificate for the exact site producing my material, plus DMF or other documentation support for my market? |
| Financial stability | Can this supplier keep investing in the plant, in quality systems and in raw material stock through a bad year? |
| Manufacturing location | Is the site a real manufacturing facility I can audit, or is the supplier a reseller of someone else’s material? |
| Clinical impact | How critical is this API to patients, and what is my plan if supply is interrupted? |
How to Prove Your Supply Chain Isn’t Fragile
If you are a formulator, distributor or procurement lead, these are practical steps that turn “we think we’re fine” into something you can show a customer or regulator.
- Map your supply chain below the supplier. Know who makes the API, and also which intermediates and starting materials sit behind it. Fragility often hides one or two steps upstream.
- Confirm the actual manufacturer. A trader’s quote is not a supply chain. Ask for the manufacturing site address and the certificate that names it. (See our guide to telling a manufacturer from a trader.)
- Check for backward integration. A manufacturer that makes its own intermediates has fewer places for a disruption to enter.
- Qualify a second source before you need one. The pantoprazole example shows that many suppliers is not the goal. The goal is a qualified, documented alternative that you could actually switch to. Do the paperwork while you have time.
- Hold a documented safety stock plan. Decide in advance how many weeks of cover you keep for critical APIs, and confirm your supplier’s lead times against that.
- Keep your documentation current. DMF references, CoAs, GMP certificates and change-notification agreements should be on file and up to date. A supplier that tells you about process changes is far less fragile than one that doesn’t.
- Audit or re-audit. An on-site or virtual audit of the production facility remains the strongest single piece of evidence.
Why Sourcing From a Real Manufacturer Reduces Fragility
Many fragility problems begin with distance between the buyer and the plant. Each added link, whether a trader, an agent or a re-packer, adds a place where information gets lost and a place where supply can quietly shift to a different source without you knowing.
Buying directly from a manufacturer shortens that chain. You get a single, controlled production source, direct access to the team that can answer process and documentation questions, and a clearer picture of lead times and capacity.
Chemox Pharma’s Approach
Chemox Pharma is a WHO-GMP certified API and intermediates manufacturer based in Dahej, Gujarat. We run our own manufacturing and have an in-house R&D centre. Our portfolio includes APIs such as Tadalafil, Citicoline Sodium, Atorvastatin, Rosuvastatin, Azithromycin and Mirabegron, along with intermediates including DMDO-CL, OLMI-1 and TTBB for Olmesartan Medoxomil synthesis.
If you are building a second-source plan or reviewing the resilience of your current API supply, our team can share facility details, GMP documentation and current availability for the products you need, so you can evaluate us on evidence.
Request a Quote and Supply Documentation
If you want to qualify a manufacturer-direct source for your API or intermediate requirement, get in touch with Chemox Pharma for a quote, sample evaluation and documentation review.
FAQs
Q: What is the National Fragility Index?
The National Fragility Index (NFI) is a benchmark launched on October 6, 2026 by the API Innovation Center, designed to measure and track structural fragility across U.S. pharmaceutical supply chains, down to individual drug product codes.
Q: What does API supply chain fragility actually mean?
It describes how vulnerable the supply of a medicine or its active ingredient is to disruption, based on factors such as geopolitical exposure, regulatory compliance, financial stability, manufacturing location and clinical importance.
Q: Does having more API suppliers reduce fragility?
Not automatically. APIIC rated pantoprazole as Severe even though its API comes from 36 suppliers in 12 countries. What matters is whether you have qualified, documented, switchable sources, not just a long vendor list.
Q: Does the index rate individual API manufacturers?
No. The NFI scores medicines, not suppliers, so no manufacturer can claim an index rating. Buyers should still verify each supplier directly through certificates, audits and documentation.
Q: How can API buyers reduce supply chain fragility today?
Map the chain below your supplier, confirm the actual manufacturer, check for backward integration, qualify a second source in advance, keep a safety stock plan and keep GMP and regulatory documentation current.
